Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by symmetrical polyarthritis and systemic inflammation. Recent studies have highlighted the critical role of the Th17/IL-17 axis in RA pathogenesis, with elevated Th17 cell frequencies and IL-17 production contributing to disease progression. Candida albicans, a commensal fungus residing in mucocutaneous surfaces, relies on Th17-mediated immunity for protection against mucocutaneous candidiasis. However, RA patients exhibit impaired Th17 responses, increasing their susceptibility to C. albicans infections. This review examines the temporal dynamics of Th17 responses to C. albicans in RA patients, analyzing the expression trends of Th17 and regulatory T cells (Tregs) over 12, 24, and 48 hours. Findings indicate that RA patients have a diminished initial Th17 response, inadequate IL-17 production at peak activity, and sustained immune dysfunction, leading to compromised fungal clearance. Additionally, biologic therapies targeting the Th17/IL-17 pathway, while effective for RA symptom management, may exacerbate infection risks. Understanding these dynamics is crucial for developing strategies that enhance antifungal immunity without aggravating RA symptoms. Further research is essential to optimize treatment protocols that balance antifungal defenses and autoimmune regulation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.